Refractory Glaucoma Treatment Market Market 2030 | Comprehensive Industry and Vendor Landscape 2030.

 Glaucoma is a growing concern worldwide, with an increasing number of individuals being diagnosed with the condition. According to the Glaucoma Research Foundation, it is the primary cause of permanent blindness globally, and even with proper treatment, around 10% of patients still suffer vision loss. In 2013, an estimated 64.3 million people had glaucoma worldwide, with a high prevalence in Africa and Latin America, as reported by the American Academy of Ophthalmology. For patients who do not respond to medication, trabeculectomy surgery is an option, but some individuals still experience glaucoma symptoms even after the procedure. As a result, new and innovative treatment options are necessary to provide relief for these patients. Lowering intraocular pressure remains the most crucial long-term medical need for individuals with refractory glaucoma.

Alternatives for Treating Refractory Glaucoma

The market for treating refractory glaucoma worldwide can be categorized by the available treatment methods and devices in the industry.

New World Medical Inc.’s Ahmed Glaucoma Valve has been a viable treatment option for refractory glaucoma since 1993. In addition to its use in refractory glaucoma, this device has proven successful in treating primary open-angle glaucoma that does not respond to medication, neovascular glaucoma, and congenital or infantile glaucoma. Numerous studies have reported positive outcomes in both pediatric and adult patients who have received Ahmed Glaucoma Valve treatment for refractory glaucoma, making it a highly sought-after and frequently utilized device around the world.

Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/71

The CyPass Micro-Stent from Transcend Medical is an alternative option that has demonstrated impressive outcomes in individuals with primary open-angle glaucoma. However, it is considered a micro-invasive procedure and is required to be conducted in conjunction with cataract surgery in accordance with FDA regulations. This has limited its widespread adoption among patients because of the associated higher expenses.

During clinical trials, the Xen System by Allergan demonstrated promising outcomes, including a 44% decrease in eye pressure and a 65% reduction in the use of IOP medications over a one-year period. The Xen gel stent functions as a permanent implant that can be adjusted by physicians to reduce IOP, even after the implantation. Allergan gained approval from the U.S. FDA for the Xen Gel stent in November 2016 and plans to launch it in the American market for refractory glaucoma treatment in early 2017. The Xen system has received the CE mark and over 10,500 stents have already been distributed worldwide. Furthermore, this new surgical system is authorized for use in Canada, Switzerland, and Turkey.

Iridex Corporation, a worldwide supplier of inventive laser systems, devices, and consumables in the field of ophthalmology, presented the favorable outcomes of its MicroPulse P3 (MP3) device at the European Glaucoma Society event held in June 2016. The MP3 device, which employs MicroPulse laser technology, exhibited long-lasting advantages for patients experiencing refractory glaucoma. Although further comprehensive research is required to confirm its effectiveness, successful outcomes from a few detailed studies could potentially lead to global acceptance of this technology in the future.

To alleviate intraocular pressure (IOP) in refractory glaucoma patients, glaucoma drainage devices are a popular treatment option. These devices can be obtained with or without IOP regulating valves. Among the valve-based drainage devices, the Ahmed glaucoma valve (AGV) is the most widely used. In contrast, non-valved drainage devices such as the Molteno, Baerveldt, Shocket, and Eagle Vision implants are available in the market as well.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/71

Dynamic Future Markets

The American Academy of Ophthalmology predicts that the global prevalence of glaucoma will increase to 76 million in 2020 and 111.8 million in 2040. The rise in prevalence will be largely driven by an aging population, particularly in Asia and Africa. However, the adoption of refractory glaucoma treatment devices in emerging nations may be limited due to the high cost of the surgery, and the fact that cataract surgery is the most commonly performed eye surgery in these regions. Despite this, the introduction of new devices and technology could drive growth in North America and Europe.

Important Events

To enhance their product portfolio, prominent market participants are concentrating on introducing novel devices. An example of this is the launch of the Ahmed ClearPath glaucoma drainage device by New World Medical, Inc., a privately held ophthalmic company, in August 2019.

In June 2019, Glaukos Corporation reported that the iStent inject Trabecular Micro-Bypass System, when implanted alone, resulted in a significant decrease in the average intraocular pressure for treating glaucoma.

To expand their product portfolio, major industry players are also utilizing acquisition tactics. In June 2019, Glaukos Corporation acquired DOSE Medical Corporation, which specializes in developing multiple micro-invasive, bioerodible, sustained-release drug delivery platforms to treat various retinal diseases, including refractory glaucoma.

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Research Antibodies Market Size Analysis from 2023 to 2030
11.6 COVID-19 Outbreak: Research Antibodies Industry Impact

Chapter 2 Global Research Antibodies Competition by Types, Applications, and Top Regions and Countries
2.1 Global Research Antibodies (Volume and Value) by Type
2.3 Global Research Antibodies (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Research Antibodies Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Research Antibodies Market Analysis
Chapter 6 East Asia Research Antibodies Market Analysis
Chapter 7 Europe Research Antibodies Market Analysis
Chapter 8 South Asia Research Antibodies Market Analysis
Chapter 9 Southeast Asia Research Antibodies Market Analysis
Chapter 10 Middle East Research Antibodies Market Analysis
Chapter 11 Africa Research Antibodies Market Analysis
Chapter 12 Oceania Research Antibodies Market Analysis
Chapter 13 South America Research Antibodies Market Analysis
Chapter 14 Company Profiles and Key Figures in Research Antibodies Business
Chapter 15 Global Research Antibodies Market Forecast (2023-2030)
Chapter 16 Conclusions
Research Methodology